Linagliptin as add‐on to empagliflozin and metformin in patients with type 2 diabetes: Two 24‐week randomized,double‐blind,double‐dummy,parallel‐group trials期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Linagliptin as add‐on to empagliflozin and metformin in patients with type 2 diabetes: Two 24‐week randomized,double‐blind,double‐dummy,parallel‐group trials

Authors:	Francisco J. Tinahones MD Baptist Gallwitz MD Matias Nordaby MD Sophia Götz Dipl. Math Mario Maldonado‐Lutomirsky MD Hans J. Woerle MD Uli C. Broedl MD

Affiliation:	1. Department of Diabetes, Endocrinology and Nutrition, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Universitario Virgen de la Victoria, Universidad Málaga, Málaga, Spain;2. CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Málaga, Spain;3. Department of Medicine IV (Endocrinology, Diabetes, Angiology, Nephrology & Clinical Chemistry), Eberhard Karls University, Tübingen, Germany;4. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany;5. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Abstract:

Keywords:	DPP‐IV inhibitor glycaemic control metformin SGLT2 inhibitor